Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.

In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.